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ABSTRACT 
Licamied Chalise Macklin: The Protective Role of Estrogen on HIV-1 Mediated 
Neurotoxicity 
(Under the direction of Dr. Jason Paris) 
 
 
The prevalence of HIV among men have been in a steady inclination over the last several 
decades, yet the accelerated infection rate among older women is considerably 
concerning. Not only does the HIV virus affect the immune system but it also affects the 
central nervous system. One of its viral proteins, Tat, acts as an excitotoxin and disrupts 
the cell’s membrane potential by increasing the concentration of Ca2+ inside the cell. This 
influx of calcium ions leads to apoptosis and secretion of the cell’s contents into the 
surrounding area. Macrophages, along with other innate immune components, gather and 
induce the release of cytokines or chemokines. However, it has been discovered that 
estrogens can be used to attenuate these harmful neurotoxic effects. Acknowledging that 
women over the age of 50 are undergoing menopause, the body’s natural levels of 
estrogen begin to decline. We hypothesized that estradiol (acting at estrogen receptor α or 
β) would attenuate Tat-mediated formation of reactive oxygen species (ROS), 
neurotoxicity, and cytokine production in differentiated SH-SY5Y human neuroblastoma 
cells and primary murine mixed glial cultures. Our findings suggest that any 
concentration of estradiol (0.01-10 nM) could attenuate Tat-mediated ROS, but cell death 
involving was not influenced. Estrogen receptor α agonism appeared more effective than 
β. Tat was also observed to increase cytokine expression. This information may be 
particularly important for medical treatments concerning aged HIV-infected women. 
Restoring estrogens post-menopausally may improve the prevalence of HIV-related 
neurocognitive impairments that occur with age.   
v 
 
TABLE OF CONTENTS 
LIST OF FIGURES……………………………………………………………vi 
LIST OF ABBREVIATIONS………………………………………………..vii 
1. INTRODUCTION………………………………………………..1 
2. MATERIALS AND METHODS…………………………………11 
2.1 DESCRIPTION OF CELLS AND CELL CULTURE 
PROCESSES……………………………………………...11 
2.2 CHEMICALS INVOLVED IN EXPERIMENTS………...13 
2.3 EXPERIMENTAL PROCEDURES USED ON CELLS….14 
3. RESULTS………………………………………………………….16 
3.1 ROS ASSAY……………………………………………….16 
3.2 LIVE/DEAD ASSAY………………………………………16 
3.3 CYTOKINE/CHEMOKINE ARRAY……………………...17 
4. DISCUSSION………………………………………………………18 
LIST OF REFERENCES……………………………………………………….23 
 
 
  
vi 
 
LIST OF FIGURES 
 
 Figure 1 ROS Produced by Cells Exposed to Tat and Varying   
   Concentrations of Estrogen Agonists PPT and DPN……...…….28 
 
Figure 2 Live/Dead Assay of Cells Exposed to Tat and Varying   
  Concentrations of Estradiol…………………...………………....29 
  
Figure 3 Cytokine/Chemokine Array of Primary Mixed Glia Cells  
  Exposed to Tat……….…………………………………….…….30 
  
vii 
 
LIST OF ABBREVIATIONS 
AIDS  Acquired Immunodeficiency Sydrome 
BBB  Blood Brain Barrier 
BDNF  Brain-Derived Neurotrophic Factor 
cART  Combined Antiretroviral Therapy 
CD4  Cluster of Differentiation 4 
CDC  Centers for Disease Control and Prevention 
CNS  Central Nervous System  
DMEM  Dulbecco’s Modified Eagle Medium 
DPN  Diarylpropionitrile 
ER-alpha Estrogen Receptor Alpha 
ER-beta Estrogen Receptor Beta 
HIV   Human Immunodeficiency Virus 
MCSF  Macrophage Colony-Stimulating Factor 
PPT   Propylpyrazoletriol 
ROS  Reactive Oxygen Species 
Tat  Trans-Activator of Transcription 
 
 
  
 
1. Introduction 
a. HIV incidence within the U.S. and worldwide 
Human immunodeficiency virus, or HIV, has affected millions of people around the 
world for decades and continues to affect people today. The beginning of this epidemic in 
1981 seemingly only affected the homosexual population, or males who have sex with 
males (MSM). However, it was clear that the epidemic was spread by 1983 (“A Timeline 
of HIV and AIDS,” 2018). HIV can be transmitted only through certain bodily fluids 
such as blood, semen, and anogenital fluids ("HIV Transmission," 2017). It has been 
discovered that semen from HIV-infected men can eventually spread the virus through 
contact via mucosal membranes and barriers during sexual intercourse (Barre-Sinoussi, 
2014). In addition, HIV can be transmitted via several routes including the birth canal and 
contaminated breast milk from the mother ("HIV Transmission," 2017). This method of 
transmission has drastically decreased due to an increase in HIV screening of pregnant 
women, antiretroviral treatment and avoidance of breastfeeding when infected (Brady et 
al., 2016). Lastly, HIV can also be spread through the sharing of needles and syringes 
from an infected drug user ("HIV Transmission," 2017). Like mother-to-child 
transmission, this route of transmission can also be decreased via the initiation of Syringe 
Exchange Programs (SEP) such as those that have been successful in major cities like 
New York City (Amesty et al., 2011). Although all of these routes of transmission have 
decreased due to recent therapeutic medications and treatments, there is currently no cure 
available that can resolve the epidemic.  
When the epidemic’s first cases were reported in 1981, the Centers for Disease 
Control (CDC), had identified five relatively healthy, young gay men that had 
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mysteriously died from a suspected lung infection. Yet, by the end of the year, the total 
had risen to two hundred and seventy cases and one hundred and twenty-one of them had 
died. That is equivalent to forty-four percent mortality rate with an unknown etiology. By 
1989, the number of cases within the United States had risen to 100,000 (“A Timeline of 
HIV and AIDS,” 2018). Today, the rate of incidence around the world has slowed but not 
reversed its relative direction. As reported in the European Union/European Economic 
Area, the incidence is still between 29,000 and 33,00 new cases every year until 2015 
(Pharris et al, 2015). Europe is not the only participant in this phenomenon. East and 
South Africa host the world’s largest HIV-infected population with a significant 
difference in prevalence of young women and young men. Specifically, the infection 
rates in young women are eight times higher than the rate in young men (Harrison et al., 
2015). This statistic has remained relatively stable for over a decade (Harrison et al., 
2015). A somewhat similar trend has been found within the United States, despite 
varying opinions. One source written by Lansky et al. claims that new HIV infection rates 
in the overall women population has decreased by twenty-one percent from 2008 to 2010 
(2014). Another source determined different data from around that same time frame. The 
incidence rate for young men was fifteen times higher than young women during the 
beginning of the epidemic. However, by 2010, the incidence rate was only three times 
higher among young men (Breskin et al., 2017). Despite the two slightly opposing 
ideologies, HIV still wreaks havoc on the central nervous system (CNS) and immune 
system of both sexes.  
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b. HIV effects on the body/progression to AIDS 
The HIV virus can be found within various organs and organ systems throughout the 
body. This includes the liver, stomach, lungs, and kidneys (Bednar et al., 2015). A 
prominent site of viral reservoir lies within the central nervous system. As such, this 
Thesis will focus on the HIV interactions within the central nervous system.   
The HIV virus targets the immune system of the individual it affects. Specifically, it 
predominantly infects monocyte-derived-cells, including macrophages and microglia (the 
macrophage of the brain) and T-lymphocytes, including CD4+ T cells (Nall, 2018). 
Infection of these cells limits the body’s primary adaptive immunological defense 
mechanism. In the CNS, the virus predominantly activates innate immune responders 
which produce cytokines (Nasi et al., 2014). Cytokines are signaling proteins that 
regulate immune responses, increasing or reducing inflammation (Foster, 2001). As a 
result, massive amounts of cytokines in one area often result in increased inflammation. 
Inflammation is one of the first signs that the body is attempting to fight off an infection. 
While this defense mechanism is designed to assist the body, other organ systems begin 
to degrade under stressors of this magnitude.  
The CNS maintains several regulatory mechanisms to prevent invasion given that 
there is very little adaptive immunity in the brain and spinal cord. Entry to the CNS is 
regulated by the blood brain barrier (BBB). The BBB provides biologic, physiologic, and 
immunologic separation between the periphery system and the CNS (Strazza et al., 
2011). Due to several different proteins being involved in regulatory processes, the 
barrier is also considered semi-permeable, meaning only certain chemicals and molecules 
are able to pass through the barrier. Perturbation of the BBB can promote permeability 
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(Strazza et al., 2011). Alterations of the surrounding environment can lead to changes in 
the integrity of the BBB, which ultimately leads to an increase of infected cells migrating 
across the barrier and into the CNS (McRae, 2016). HIV-infected cells that may gain 
access to the CNS can produce neuroinflammation, damaging neural cells. It is this effect 
that is thought to underlie various types of neurocognitive impairments, overall termed 
“NeuroAIDS.”  (Shapshak, 2015).   
c. NeuroAIDS Incidence and Current Therapeutic Methods 
NeuroAIDS is defined as the result of chronic and persistent HIV infection and 
inflammation (Shapshak, 2015). This disease includes various degrees of impairments, 
such as “decreased attention/concentration, psychomotor speed, memory, learning, 
information processing, and executive function” (Shapshak, 2015). The overall 
prevalence of this disease has not decreased since the introduction of combined 
antiretroviral therapy (cART); albeit, cART has reduced the incidence of the most severe 
form, HIV-associated dementia (Caniglia et al., 2014). cART refers to a therapeutic 
method of maintaining the HIV infection within the body by introducing various classes 
of drugs in the body (Boskey, 2018). This method usually includes at least two drug 
classes in order to properly stabilize the progression of the replicating virus (Boskey, 
2018). However, the main issue with this method is the drug’s inability to accumulate 
within the brain and latent reservoirs, such as macrophages and microglia in the brain. 
cART is able to infiltrate the BBB due its lipophilicity and by acting as a substrate for 
several BBB transporters (such as P-glycoproteins). In order for the cART to work 
optimally and efficiently, the drugs have to be able to enter the BBB and effectively 
maintain its efficacy within the system and within the reservoirs of latent virus (Zhang et 
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al. 2015). At present, there is no cART regimen that can eradicate HIV from viral 
reservoirs within the CNS.  
While the HIV infection is one of the major contributors to this disease, there are co-
morbid factors that can couple with HIV and further increase the risk of NeuroAIDS. One 
of the co-morbid factors that will be discussed later is menopause in middle-aged women. 
To continue with the discussion of NeuroAIDS, it was originally identified with 
individuals who had progressed to AIDS (Shapshak, 2015). However, within the same 
year, it was discovered by another research committee that neuroAIDS could also be 
found within the HIV community (Carvour et al., 2015). In fact, nearly half of HIV-
infected individuals who had not progressed to AIDS were diagnosed with neurological 
complications due to NeuroAIDS (Carvour et al. 2015; Saylor et al., 2016).  
d. HIV proteins (Tat) that contribute to NeuroAIDS 
One viral protein that also contributes to the progression of NeuroAIDS is an HIV 
regulatory protein. Known as the trans-activator of transcription, or Tat, it has an 
important role in the replication cycle of HIV to enhance gene transcription and viral 
replication (McRae, 2016). In addition to its regulatory function, Tat is soluble, can be 
secreted from infected cells, and cause several disastrous effects on the CNS. Tat 
increases in cytokine production and promotes immune cell migration across the BBB 
(McRae, 2016).  Tat also exerts direct neurotoxic effects by acting as an excitatory signal, 
causing Ca2+ channels to open and disrupting cellular ion homeostasis. In disrupted cells, 
mitochondria work to absorb excess Ca2+ which causes the organelle to release reactive 
oxygen species, which promote cell death (Fitting et al., 2014).  Even if the individual 
begins cART, the issue described earlier arises again, in addition to a new problem. 
6 
 
While on cART, it has been discovered that transcription of viral proteins continues. This 
results in "cytotoxic stress, inflammatory response and tissue integrity damage, all of 
which are major contributors to [NeuroAIDS] development and progression” (Bagashev 
and Bassel, 2013). Thus, production of toxic proteins from persistent reservoirs of HIV 
within the brain could underlie the cause of neuroAIDS, even in the post-cART era.  
Additionally, several scientific studies have identified a significant sex difference 
regarding the overall maintenance and survival rates with this neurodegenerative disease.  
e. NeuroAIDS in pre and post-menopausal women 
According to previous studies, HIV-infected women perform lower on cognitive tests 
and survive at lower rates than their male counterparts. One research team made the 
discovery that women aged 37-38 displayed a lower survival time than men (Carvour et 
al, 2015). The two groups had several events measured. One of the events measured was 
the time between diagnoses of HIV and AIDS; women were observed to have less time 
than men (Carvour et al., 2015). The rate of death was also higher among women 
compared to men. Lastly, the overall survival time from initial diagnosis to death was 
lower than men (Carvour et al., 2015). This study provides several examples that there is 
a factor affecting the survival rates among women.  
Another study displayed similar results with different events. Groups of HIV+ 
and HIV-women were cognitively tested using a memory test. The HIV+ women 
showcased impairments in verbal learning, verbal delayed recall, figural episodic 
memory, and working memory (Maki et al., 2009). The average age of these women were 
slightly higher at 41.95 years old (Maki et al., 2009). This observation of similar results 
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in slightly older women indicates there is an additional method contributing to the 
progression and decline of women with NeuroAIDS. 
f. Estrogens and their effect on NeuroAIDS 
 Estrogen is most commonly known as a steroid hormone that is involved in sexual 
differentiation and development of males and females (Wilson et al., 2006). There are 
two main types of receptors found throughout the brain and CNS that contribute to 
memory and other cognitive abilities. ER-alpha, is a receptor that is found throughout the 
brain, but predominantly in the hypothalamus, the area of the brain that is critical for 
reproductive signaling. ER-beta expression is distributed throughout the CNS, but 
predominantly in the hippocampus, a brain region largely associated with emotion and 
cognition (Wilson et al., 2006). Some evidence suggests that estradiol is neuroprotective. 
While the exact mechanisms that may underlie its role in neuroprotection and extent to 
which they interact with sex differences are not fully understood, they are beginning to be 
examined. 
 One key difference between HIV-infected men and women is that women have 
been shown to be more sensitive to the development of neuroAIDS (Maki and Martin-
Thormeyer, 2009). One study that was conducted in Europe was indicative that women 
were twice more likely to develop neuroAIDS than men (Chiesi et al., 1996). Yet, 
another study conducted in the United States was indicative that there was no sex 
difference in the development of neuroAIDS (Robertson et al., 2004). Given the variance 
in these data, further investigation is necessary. Another study by Weber et al. indicated 
that certain cognitive deficits are believed to be caused by changing levels of estrogen 
during the menopausal transition (2012). HIV-infected women greater than the age of 
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forty had a higher incidence of dementia than women who were younger than forty 
(Wilson et al., 2006). Some have suggested that neurological complications from AIDS is 
associated with low estrogen levels. Now, it is important to discuss how estrogen 
interacts with one of the main viral proteins associated with HIV. 
g. Estrogen and its interactions with Tat 
 HIV-1 protein Tat is thought to play an important role in the neuropathology of 
HIV and hormone levels in women may influence these effects (Adams et al., 2010). 
Postmenopausal HIV-infected women have a higher risk for experiencing neurocognitive 
deficits that are associated with the low levels of estrogen (Wallace, 2006).  More recent 
work suggests that the presence of estrogen may slow the progression of HIV and protect 
against the toxicity of Tat in humans (Wallace, 2006). An experiment performed using 
neural cells determined that estrogen was able to delay cell death by constricting the 
apoptotic signal produced by Tat (Adams et al.,2010). The pressing question then arose: 
which estrogen receptor, if any, was mainly responsible for neuroprotection. Using 
particular antagonists, it was discovered that ER-beta signals were preferred but ER-alpha 
signals still contributed to the neuroprotection (Adams et al., 2010).  
 Yet, another study conducted by Heron et al. determined results that ER-alpha 
was the primary receptor involved in the neuroprotection against Tat (2009). This 
research team used different methods, such as using agonists. The team investigated the 
effects of ER-beta, but the resulting levels were almost negligible compared to the 
resulting levels of ER-alpha (Heron et al., 2009). As a result, the team decided not to 
further isolate and investigate the effects of ER-beta. Although these two studies 
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produced different results, the importance of estrogen remains significant, especially in 
its effects on the CNS.  
h. Estrogenic Hormone Therapy and its effects on the CNS 
 Although estrogen has been considered protective on a concentration dependent 
interaction, these natural levels deplete on their own after a woman enters menopause. 
According to a 2016 survey of new HIV diagnoses, seventeen percent were fifty and 
older and twenty-four percent of that number were women (CDC, 2018). A possible 
solution to this increasing problem lies in hormone replacement therapy. The procedure 
involves the woman enhancing her natural levels of estrogen via several routes: pills, skin 
patches, gels, creams, vaginal creams, vaginal tablets, or vaginal rings (“Hormone 
Therapy: Is It Right For You?”).  
 Due to estrogen’s substantial anti-inflammatory and neuroprotective properties, it 
should be considered as a therapeutic method to counteract inflammation in the brains of 
HIV-infected menopausal women (Dye et al., 2012). Since there have been various 
reports and observations of the benefits of estrogen on the CNS, it has led to a suggestion 
that older women have their estrogen levels maintained throughout and after menopause 
(Dye et al., 2012). One study demonstrated that a group of older HIV-infected women 
who had been placed on hormone replacement therapy had a significantly decreased risk 
of mortality (Dye et al., 2012).  
i. Hypothesis  
 To assess the neuroprotective mechanisms of estrogens, we conducted a series of 
experiments using differentiated human neuroblastoma cells and murine primary mixed 
glia. We anticipated that exposure to HIV-1 Tat would increase reactive oxygen species 
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formation and cell death in neurons. In glia, we expected Tat to increase cytokine 
production. Agonists with selective affinity for ER-alpha (PPT), ER-beta (DPN), or both 
(estradiol) were expected to attenuate these effects.   
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2. Materials and Methods  
2.1 Description of Cells and Cell Culture 
a. SH-SY5Y human neuroblastoma cells  
These cells originate from the bone marrow of a four-year old female patient with a 
metastatic neuroblastoma. The morphology of SH-SY5Y cells are epithelial, however, all 
of the experiments performed are used with cells that have been differentiated into a 
neuron-like phenotype. Cells were grown in a 75 cm2 cell culture flask in 10 mL of media 
(89.5% DMEM/F12, 10% fetal bovine serum, 0.5% antibiotics). The flasks were then 
maintained in an incubator at 37° C with 5% CO2.  
For experimental manipulation, cells were seeded onto 24-or 96-well plates at 
seeding densities of 50,000 or 5,000 cells per well, respectively. To differentiate SH-
SY5Y cells to a neuron-like morphology, retinoic acid (1:500) was supplemented in the 
media for 5 days. Following this, cells were maintained in serum-free BDNF (1:200) 
media for additional 3 days per prior protocols (Constantinescu et al.,2007; Encinas et al., 
2000). For all experiments, media was fully changed every 48 hours.  
b. Primary Mouse Mixed Glia Cells 
Primary mixed glia were cultured from 0-1-day old mice (C57BL/6HNsd 
purchased from Envigo, Indianapolis, IN) as previously described (Paris et al., 2016). 
Briefly, brains were harvested and minced with trypsin (2.5 mg/ml) and DNase (0.015 
mg/ml) in DMEM and incubated for 30 min (37°C, 5% CO2). Tissues were triturated and 
sequentially filtered through 100-lm and 40-lm diameter pore cell strainers (Greiner Bio-
One, Kremsmünster, Austria). Cells were plated at a density of 50,000 cells/well onto 
poly-L-lysine-coated 24-well culture plates and maintained for 10-12 days in DMEM 
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supplemented with (10% fetal bovine serum, 0.5% antibiotics, 0.5% glucose, and 0.13 
sodium bicarbonate). Media was fully changed every 48 hours.   
Before the cells are collected, multiple 24 well plates were made with a certain 
chemical mixture called Poly-L-Lysine. The mixture is combined with 50 µL stock 
solution (100 mg/mL stored in -80°C freezer) and 10 mL of borate buffer solution. 200 
µL of the mixture was added to each well and left for a 3-hour incubation period. Once 
that amount of time had passed, the mixture was removed and replaced with distilled H2O 
every 15 minutes, for a total of 6 washes. The last wash was removed and then left to air 
dry in the hood overnight. The mixed glia cells were collected from newborn to 2 days 
old C57 murine pups and placed into petri dishes. The dishes are then placed into the 
incubator at 37°C and 5% CO2. The cells had their 10% FBM media changed every 48 
hours to ensure the optimal growth. For a 200 mL solution, there is 175 mL of DMEM, 
3.5 mL of 7.5% Sodium Bicarbonate, 2 mL of 50% glucose, 1 mL of Pen/Strep, and 20 
mL of FBS.  
c. Process of Treatment 
Once the cells in the 24 or 96 well plates were growing at a steady rate, they had 
to be differentiated into neuronal cells. Several chemicals are added in order to assist this 
process. First, Retinoic Acid (50 mg retinoic acid, 33.3 mL 95% EtOH) would be added 
to the flask in a 1:500 dilution with DMEM media.  The purpose of this chemical is to 
begin differentiation of the cells. After approximately 5 days, BDNF (10 µg BNDF, 1 mL 
DMEM/F12) was added to the flask to continue the differentiation process. After 
approximately 3 days, the original cells have completely differentiated into neuronal-
shaped cells. This shape consists of a star-shaped cell where the dendrites of the neuron 
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are connecting and communicating with the other cells around it. This was a clear 
indication that the cells were ready to be treated with chemicals for an experiment. In 
addition, the DMEM/F12 media was changed every 48 hours and returned back to the 
incubator to continue growth.      
2.2 Chemicals Involved in Experiments 
a. 17-β Estradiol (E2) 
Estradiol (Sigma-Aldrich, St. Louis, MO) has been determined through past and 
current research that estradiol additionally serves as a protective agent in the brain. 
Estradiol has been proven to be beneficial in memory function. It has equal affinity for 
ER-alpha (ki: 0.12 nM) and -beta (ki: 0.15 nM; Lund et al., 2005). Crystalline estradiol 
was dissolved in DMSO and diluted to concentration in media.  
 Propylpyrazoletriol (PPT) 
This chemical is an agonist for the estrogen receptor alpha (ER-alpha ki: 0.5 nM; 
ER-beta ki: 700 nM; Lund et al., 2005). Crystalline PPT was dissolved in DMSO and 
diluted to concentration in media.    
b. Diarylpropionitrile (DPN) 
DPN is an agonist for the estrogen receptor beta (ER-alpha ki: 195 nM; ER-beta 
ki: 2.5 nM; Lund et al., 2005). Crystalline DPN was dissolved in DMSO and diluted to 
concentration in media.   
c. Transactivator of Transcription (Tat) 
The HIV Tat protein exerts indirect neurotoxic effects by promoting 
neuroinflammation and also produces direct neurotoxic effects via several mechanisms 
including direct or indirect excitotoxic activation of Ca2+ ion channels (NMDA receptors 
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and voltage-gated L-type Ca2+ channels; Eugenin et al., 2007; Haughey et al., 2001; 
Krogh et al., 2014; Napier et al., 2014), mitochondrial dysfunction which produces 
reactive oxygen/nitrosative species (Hui et al., 2012; Lecoeur et al., 2012; Malik et al., 
2011; Turchan-Cholewo et al., 2006), and leads to subsequent bioenergetic crisis and cell 
death. Tat (ImmunoDx, Woburn, MA) was diluted to 100 nM in water. The concentration 
of tat reflects one from a range that elicits functional deficits in glia and neurons similar 
to those observed in HIV infection (Kruman et al., 1998; Nath et al., 1999).  
2.3 Experimental Procedure 
a. Reactive Oxygen Species (ROS) Assay 
 The generation of ROS is an early indicator of mitochondrial stress and 
cellular dysfunction. Cells were intubated with treatments for 20 hours and then assessed 
for fluorescence in the presence of 5- (and-6)- chloromethyl-2’7’-
dichlorohydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, Invitrogen, Carlsbad, 
CA) as previously described (Fitting et al., 2014). Briefly, cells were loaded with 10 µM 
CM-H2DCFDA in warm HBSS for 45 min (per manufacturer’s protocol), and washed 
twice. Fluorescence was measured at λex= 485 nm and λem= 520 nm using a Bio Tek 
(Winooski, VT) Synergy 2 microplate reader. All treatments were performed in duplicate 
and each plate counted as one observation (the mean of technical replicates per 
condition). Data are expressed as the percent change from the arbitrary fluorescent units 
in control wells and represent n= 4 independent experiments.  
b. Live/Dead Assay 
DEAD Red (propidium iodide), a marker of cellular necrosis, and nuclear 
Hoechst 33342 stain (Invitrogen, Carlsbad, CA) were added to media. Treatments of 
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Estradiol in 0.01 nM, 0.1 nM, and 1 nM concentrations were applied and plates were 
imaged 0, 24, and 48 hours later. DEAD Red fluorescence was measured at λex= 570 nm 
and λem=602 nm and Hoechst was measured λex=350 nm and λem= 461 nm. Each 
condition was conducted in duplicate and each plate was counted as one observation (the 
mean of two technical replicates per condition). Fields were randomly determined and at 
least 150 cells were counted per field. The proportion of cellular death was determined by 
the following formula: % dead= (# DEAD Red+ cells/ # Hoechst+ cells) *100. Data 
represent n=8-10 independent experiments.  
c. Cytokine Array 
 The purpose of the cytokine protein array was to screen potentially upregulated 
cytokines and chemokines in order to discover future analytical targets. The array 
(Proteim Profiler Mouse Cytokine Array Kit, #ARY006, R&D Systems, Minneapolis, 
MN) assessed the protein content of the following analytes. The assay was conducted per 
manufacturer instructions and blots were read on a LI-COR imager.  
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3. Results  
3.1 ROS Assay  
Given that phenol red (a common component included in cell media) contains 
phytoestrogenic activity, cells were assessed after incubation in phenol red-containing 
media or phenol-red free media. Altering the growth media from phenol red to phenol-red 
free had a significant effect on the amount of ROS that was detected [F(1,108)=43.67, 
p<0.05] (Fig. 1a and 1b). Cells grown in the phenol red that were treated with additional 
estrogen agonists displayed less production of ROS than the cells in the phenol-red free 
media. It appeared that incorporation of estrogen receptor agonists along with the natural 
estrogen additives of the phenol red media created additional protection against the 
neurotoxic effects of Tat and significantly decreased cell death. Since the phenol-red free 
media does not contain any estrogen additives, the minute addition of estrogen receptor 
agonists was not enough to provide sufficient protection, thus the elevated amount of 
ROS production and cell death. Although there were no other significant findings, it 
should be noted that Tat displayed an apparent increase in toxicity.  
3.2 Live/Dead Assay 
Cells were grown in media with or without estrogenic phenol red. There was a 
significant interaction [F(3,66)=3.07, p<0.05] such that Tat significantly increased cell 
death when grown in phenol red containing media (Fig 2a and b). Cell death was 
significantly greater in phenol-red free media; as such, no additional death was observed 
with Tat (Fig. 2c and d).  A concentration-response of estradiol was tested to determine if 
a specific amount provided protection. It appeared the lowest dose of E2 (0.01 nM) 
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decreased the Tat toxicity in phenol red media only; however, this did not reach statistical 
significance (p=0.14).  
3.3 Cytokine and Chemokine Assay 
Cytokines and chemokines are the body’s immune hormones. The result of these 
chemicals secreted by glial cells can cause indirect damage to neurons within the brain. 
The purpose of testing Tat under these conditions was to determine the indirect 
neurotoxicity of the viral protein. Application of Tat to primary murine mixed glial 
cultures significantly increased chemokine (Fig. 3a) and cytokine (fig. 3b) production, 
albeit these observations were descriptive (n=2/group) and were not statistically-
analyzed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
4. Discussion 
The initial hypothesis involving the increases of various Tat-induced 
inflammatory responses and the attenuation of these responses using a concentration 
dependent interaction of estrogen agonists were partly upheld. The findings from the 
ROS assay supported that the addition of Tat would cause a direct increase of ROS in 
SH-SY5Y cells. The findings from the cytokine/chemokine array provide additional 
information about how Tat indirectly affects and influences the surrounding cells and 
tissues by stimulating proinflammatory and anti-inflammatory chemicals from glial 
sources that can damage the neurons. The findings from the live/dead assay demonstrated 
that Tat can cause direct neurotoxicity on SH-SY5Y cells that estrogenic phenol red was 
neuroprotective. Albeit, no dose-response protection with estradiol was observed, 
contrary to expectation.   
We anticipated that the addition of Tat to neural cells would increase the 
production of ROS. Once Tat has become introduced into the cell, it activates excitatory 
ion channels, such as Ca2+ channels, and cause them to open, disrupting the membrane 
potential (Fitting et al., 2014). Whenever a cell has a dysregulation influx of Ca2+ ions, 
mitochondria attempt to maintain homeostasis, in part by “hiding” the cation charge, 
storing excess Ca2+ within its own membrane. However, as the mitochondria continue to 
store these cations, ROS is produced as a consequence and mitochondrial membrane 
potential becomes compromised (Fitting et al., 2014). This event is usually the first to 
occur following cell death. Extensive ROS production and downstream events eventually 
lead the cell to undergo apoptosis. These events promote an influx of macrophages to 
accumulate within the CNS. These macrophages then lead to the stimulation and 
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secretion of cytokines and chemokines, which were also tested in this experiment. The 
media of the ROS assay was then manipulated to further contribute to the hypothesis that 
estradiol would attenuate these effects. By incorporating media that contained additional 
estrogens, the amount of ROS was significantly decreased compared to the amount of 
ROS in media without these added estrogens.  
 While there have already been several studies confirming that estrogen was in fact 
neuroprotective, there is a paucity of studies identifying the receptor-based mechanism of 
these actions. One study pursued this question and determined that ER-beta was the 
primary source of protection (Adams et al., 2010). The method of obtaining these data 
was contrary to the method used in our experiment in that prior investigations used 
antagonists whereas the current study uses agonists. It was discovered that ER-beta 
signals were preferred but ER-alpha signals still contributed to the neuroprotection 
(Adams et al., 2010). In another study conducted by Bertand et al., similar results were 
produced using a chemical called S-Equol to display how estrogen played a role in 
neuroprotection (2015). By using both enantiomers of the chemical, the team was able to 
confirm that equol provided neuroprotection in an estrogen-dependent manner and that 
both acted in an ER-beta-dependent mechanism (Bertrand et al., 2015). According to our 
results, it appears as if the ER-alpha agonists produced the most neuroprotection against 
the toxic effects of Tat. Given the research studies mentioned in the introduction that 
either receptor could be the primary cause, the results of this study coincide with the 
general concept of estradiol protecting the neurotoxic effects of Tat on neural cells. 
Additional studies should be performed to further access the extent of a receptor-
dependent mechanism involved in the neuroprotection of microglia cells.  
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HIV does not infect neurons. Rather, neuronal damage must occur by indirect 
mechanisms including that caused by toxic viral proteins, such as Tat (King et al., 2006). 
The secretion of Tat from infected cells into local tissues activates surrounding microglial 
cells leading to the secretion of defense chemicals: cytokines and chemokines (King et 
al., 2006). Cytokines and chemokines are a particular type of proteins that are released 
when the body is under attack from foreign bodies; they can stimulate or inhibit 
inflammation and contributes to cognitive impairment in HIV-infected individuals (King 
et al., 2006). Tat induced some anti-inflammatory cytokines, but the majority of the 
cytokines stimulated were pro-inflammatory. These results directly coincide with the 
previous studies that state that Tat induces inflammation in the CNS and surrounding 
tissues. In addition, there was no significant increase among the chemokines with the 
exception of CCL2 and MCSF. CCL2 is a chemokine that stimulates the immune system 
to sites of tissue injury or infection (Deshmane et al., 2009). A significant increase of this 
specific chemokine further supports previous evidence about Tat’s neurotoxic effects. 
Lastly, a significant increase was noted in the chemokine MCSF, which is coincidently 
linked to the aforementioned CCL2. This chemokine also stimulates the production of 
immune-regulated inflammatory proteins (Baran et al. 2007). By implementing the 
cytokine and chemokine arrays into my experiment, the results can be used to display the 
indirect, inflammatory effects of Tat on the surrounding tissues and neuronal cells that 
eventually lead to cognitive deficits.  
Although these cognitive impairments may seem inevitable, estrogen can be used 
to lessen the overall neuronal damage caused by Tat and its toxic effects on the CNS. 
Through my research, it was determined that ER-alpha was the primary source of 
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neuroprotection. These findings do not support my original hypothesis; however, they are 
just as influential towards discovering an alternate method for the HIV community. 
Further studies should aim to create a possible treatment method for the HIV-infected 
community that takes advantage of estrogen’s potentially neuroprotective capacity. 
The current results produced must be considered with some caveats. Some 
unforeseen complications were discovered that should be taken into account in future 
studies. In particular, the live/dead experimental approach should be amended. The 
protocol used in this experiment was not maintained throughout the duration of the 
research. A portion of the plates had the fluorescent dye incorporated in the media during 
all of the time lapses. Once an extremely high death rate was observed, it was discovered 
that the dye was intended to be added before the 24- and 48-hour time frames. The other 
portion of the plates were then conducted using the appropriate protocol and recorded 
that the death rate had been lowered. Future experiments could use the latter protocol, 
referred to as end-point analysis, when the fluorescent dye is added at the beginning of 
the 24-hour time lapse. Another option is referred to as time-lapse microscopy, which 
does not involve fluorescent dyes but analysis of specific areas over a 72-hour period. 
 Nonetheless, each of the testing methods served an influential purpose: the 
cytokine/chemokine array uncovered what specific antibodies can be quantitatively tested 
using ELISA, the Live/Dead assay showed that there should be more increments of 
estrogen doses across the plate, and the ROS assay showcased that more observations 
would be more likely to create more viable results.  
In conclusion, the findings from these sets of experiments re-solidified essential 
pieces of information that had been proven through various studies over the years. 
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Understanding how Tat indirectly, and directly, affects the human body and CNS is 
mandatory in order to properly create a beneficial method for the HIV community. 
Through dose-specific incorporations of estrogen, the entire CNS can be partially 
protected by the detrimental effects of Tat on the nervous tissue in the brain. By 
continuing research and using updated resources, the next major therapeutic method for 
the HIV-infected community can be discovered. Not only will this resource be able to 
help the current group of older women but it will also be able to protect the upcoming 
generation of women and prolong their lives to its maximum potential.  
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        Figure 1a      Figure 1b 
 
Figure 1. Differentiated SH-SY5Y cells maintained in media that (a) did or (b) did not 
contain a phenol-red indicator were exposed to vehicle, Tat (100 nM), and concurrent 
vehicle, PPT, or DPN (0.01-10 nM). Cells were assessed for the formation of reactive 
oxygen species using the indicator, DCFDA.  
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Figure 2. Differentiated SH-SY5Y cells maintained in media that (a,b) did or (c,d) did not 
contain a phenol-red indicator were exposed to vehicle, Tat (100 nM), and concurrent 
vehicle or estradiol (0.01, 0.1, or 1.0 nM; presented in Log10 concentration). The 
proportion of necrotic cells (propidium iodide-positive) was calculated (Hoeschst 33342 
used as a nuclear marker) 24 h after treatment. * indicates significant difference from 
vehicle-treated controls, p < 0.05. 
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 Figure 3a      Figure 3b  
 
Figure 3. Primary murine mixed glial cells were exposed to vehicle or Tat (100 nM) and 
assessed for semi-quantitative (a) chemokine and (a) cytokine content using a Proteome 
Profiler Mouse Cytokine Array Kit.  
